SUBSCRIBE
SUBSCRIBE
Gail Dutton

Gail Dutton

Freelance writer

Gail Dutton is a veteran biopharmaceutical reporter, covering the industry from Washington state. You can contact her at gaildutton@gmail.com and see more of her work on Muckrack.

Bio NC
Bioscience and Healthcare of the Future: Overrun by Choices, Changes and Opportunities
“The future will be overrun by an army of new choices and changes in attitudes towards one’s own health. That creates a whole new area for bioscience and health, and for investing,” Mike Edelhart, managing partner, Social Starts & Joyance Partners said.
December 18, 2020
 · 
5 min read
 · 
Gail Dutton
Drug Development
Building Better Virus Countermeasures — J&J’s BLUE KNIGHT™ Symposium Shows What’s Coming
With the first wave of vaccines gaining regulatory approval, nascent biotech companies are looking toward the future, exploring new technologies to make vaccines more effective for more people.
December 17, 2020
 · 
4 min read
 · 
Gail Dutton
Photo courtesy of Quanterix.
Drug Development
Non-Invasive Alternatives to PCR Testing Yield Accurate Results
Detecting the presence of SARS-CoV-2 in asymptomatic individuals has been a challenge not even PCR – the gold standard of testing – can adequately address. Now two companies have developed novel solutions with the sensitivity and specificity needed to provide ample warning.
December 16, 2020
 · 
4 min read
 · 
Gail Dutton
Biotech Bay
Eureka’s InvisiMask™ Anti-SARS-CoV-2 Nasal Spray Protects for 10 Hours in Preclinical Results
Eureka Therapeutics’ InvisiMask™ Human Antibody Nasal Spray can provide 10 hours of protection from SARS-CoV-2 virus in animal models, according to preclinical results released today. Now it’s heading to clinical trials.
December 14, 2020
 · 
5 min read
 · 
Gail Dutton
Drug Development
MEDSIR IDs Drugs & Biomarkers for Best Palbociclib+Endocrine Therapy Success
Palbociclib is the standard of care for patients with advanced breast cancer, yet researchers still have no molecular profile to predict which patients will progress, which will continue benefitting from this therapy after their initial treatment, and which combination therapies are most effective.
December 11, 2020
 · 
4 min read
 · 
Gail Dutton
Drug Development
Aridis’ At-Home COVID-19 Therapy and Other Programs Primed for 2021 Inflections
Aridis’ COVID-19 therapy is particularly exciting. AR-711 is an inhaled, self-administered, at-home treatment for mild-to-moderate SARS-CoV-2 infections.
December 10, 2020
 · 
5 min read
 · 
Gail Dutton
Michael Candelori/Shutterstock
Policy
Trump Prioritizes Vaccine for U.S.; USC Projects $5 Trillion in Economic Losses from Pandemic
President Donald Trump signed an Executive Order on Tuesday that ensures the U.S. government prioritizes delivery of COVID-19 vaccines to American citizens before sending it to other nations.
December 9, 2020
 · 
4 min read
 · 
Gail Dutton
Bioniz’s 3-Pronged Anti-Cytokine Therapy Halts Rare Cancer Proliferation and Inflammation
Data from a Phase I/II clinical trial was presented Saturday during the 62nd ASH Annual Meeting and Exposition (ASH).
December 8, 2020
 · 
4 min read
 · 
Gail Dutton
Drug Development
RT-PCR’s Days Are Numbered as Faster, Better, & Cheaper COVID-19 Assays Emerge
Nucleic-acid-based assays are the gold standard for detecting the presence of the SARS-CoV-2 virus, but they eventually will be replaced with simpler and more advanced techniques, such as CRISPR-Cas, LAMP, and other faster and less-expensive methods.
December 4, 2020
 · 
4 min read
 · 
Gail Dutton
Michael Vi/Getty Images, Mark Wildgust_Janssen Bio
Drug Development
Can Janssen Cure Cancer? Its 80+ ASH Presentations Suggest It’s On the Right Track
With 36 Janssen-sponsored studies and another nearly 50, it has supported, the Janssen Pharmaceutical Companies of Johnson & Johnson has a presence in more than 80 of the hematology studies presented at the 62nd American Society of Hematology (ASH) Annual Meeting & Exposition, December 5-8.
December 4, 2020
 · 
4 min read
 · 
Gail Dutton
Business
Why is the FDA Taking So Long to Review a COVID-19 Vaccine?
the robustness and independence of FDA review – even under an EUA – is an important factor in encouraging a skeptical public to accept COVID-19 vaccinations.
December 3, 2020
 · 
4 min read
 · 
Gail Dutton
Business
Convincing People to Get COVID-19 Vaccinations Will Likely Require Anecdotes and Data
With two COVID-19 vaccines pending eminent FDA review, the biggest hurdle to widespread vaccinations is simply convincing people to be vaccinated.
December 1, 2020
 · 
5 min read
 · 
Gail Dutton
Policy
Final Ruling on Medicare Most-Favored-Nation Drug Pricing Set for Federal Register Publication
The interim final rule aligns payment for Medicare Part B therapeutics with international prices and removes incentives for physicians to prescribe more expensive drugs and biologics.
November 25, 2020
 · 
5 min read
 · 
Gail Dutton
Andrey Zarur, Ph.D., president and CEO of GreenLig
Business
Harnessing Nature for Faster mRNA Vaccine Manufacturing
Manufacturing capacity is often decried as a major bottleneck in administering COVID-19 vaccines to a global population of 7.8 billion. For mRNA vaccines, the bottleneck is the availability of raw materials, not bioreactors.
November 25, 2020
 · 
3 min read
 · 
Gail Dutton
From Acne to Cancer, BiomX Infects Bad Bacteria with Modified Viruses
While many microbiome therapies rely on adding bacteria, like probiotics, Israel-based BiomX takes a somewhat unique approach of removing harmful bacteria.
November 24, 2020
 · 
4 min read
 · 
Gail Dutton
Load More